Insights & Discussion
Yu Ping Feng San, a Chinese herbal medicine, combined with pharmacotherapy could be effective for treating allergic rhinitis in adults.
The paper evaluates Chinese herbal medicine, YPFS, for treating allergic rhinitis in adults by conducting a meta-analysis and subgroup meta-analyses of several randomized controlled trials (RCTs). Seven databases were searched from their inceptions to September 2017 where RCTs evaluating YPFS for adult allergic rhinitis were included. The Cochrane risk of bias tool was used to assess the methodological quality of these studies and meta-analysis and subgroup meta-analyses were conducted to evaluate the effectiveness of YPFS.
Based on the results, YPFS when used in combination with pharmacotherapy seemed to be more effective than using pharmacotherapy alone for treating allergic rhinitis. The paper highlighted an alleviation of four individual nasal symptom scores post YPFS combination treatment; these being itchy nose, sneezing, blocked nose, and runny nose. Furthermore, it was found that the YPFS combination treatment was more beneficial when it was used for more than three weeks. The paper also mentions that YPFS was safe and well-tolerated for treating adult allergic rhinitis. However, it did not seem to be superior to the second-generation antihistamine.
Discover Related Insights
The use of Yu Ping Feng San for pediatric allergic rhinitis appears relatively safe compared to Western medical therapy yet its routine use remains unsupported.
2021 Medicine Yu ping feng san for pediatric allergic rhinitis Liao Y, Zhong J, Liu S, Dai M, Liu Y, Li X, et al.
Systematic Review Children's Health Yu Ping Feng San
The study undertakes a systematic search across multiple databases, including PubMed, the Excerpta Medical Database, Cochrane library and more, for randomized controlled trials (RCTs) concerning the use of YPFS for pediatric allergic rhinitis. Extracted results were subjected to stringent bias-risk analysis based on the Cochrane Handbook. A meta-analysis was then implemented using RevMan 5.3 software, and the Grading of Recommendations Assessment, Development and Evaluation methodology was applied to check the quality of evidence for every outcome.
The study pooled 10 RCTs covering 1,069 participants aged between 3-15 years for initial inclusion. After certain exclusions, it was determined from the remaining eight RCTs that the overall efficacy did not show any notable advantage for the test group. In addition, inspections into variation of serum immunoglobulin levels showed no statistical significance. However, the safety of YPFS displayed better results, demonstrating a relatively safer approach with lower recurrence rates compared to Western medical therapy.